With its recent $50 million VC round, the British bioinformatics firm is targeting growth in new applications as it accelerates tertiary data analysis.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.